Get started
Author

Michio Sawada

Observed name: Sawada, Michio
OpenAlex ID: A5111999364
Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy
2005 · Shinji Takai, Hisashi Tsurumi, et al. · European Journal Of Haematology · 95
Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin?s lymphoma: in combination with the International Prognostic Index
2004 · Hideko Goto, Hisashi Tsurumi, et al. · Journal of Cancer Research and Clinical Oncology · 66
A phase II study of a THP‐COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B‐cell lymphoma
2007 · Hisashi Tsurumi, Takeshi Hara, et al. · Hematological Oncology · 48
Serum-soluble Fas level determines clinical symptoms and outcome of patients with aggressive non-Hodgkin's lymphoma
2000 · Takeshi Hara, Hisashi Tsurumi, et al. · American Journal of Hematology · 43
Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin?s lymphoma
2004 · Hisashi Tsurumi, Toshiki Yamada, et al. · Journal of Cancer Research and Clinical Oncology · 42
R‐THP‐COP versus R‐CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open‐label, noninferiority phase 3 trial
2018 · Takeshi Hara, Takeshi Yoshikawa, et al. · Hematological Oncology · 39
Serum‐soluble tumor necrosis factor receptor 2 (sTNF‐R2) level determines clinical outcome in patients with aggressive non‐Hodgkin's lymphoma
2006 · Naoe Goto, Hisashi Tsurumi, et al. · European Journal Of Haematology · 39
Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U)
2008 · Jun-ichi Kitagawa, Takeshi Hara, et al. · Journal of Cancer Research and Clinical Oncology · 35
Fas and Fas ligand expression on germinal center type‐diffuse large B‐cell lymphoma is associated with the clinical outcome
2006 · Yasushi Kojima, Hisashi Tsurumi, et al. · European Journal Of Haematology · 34
PDF
Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone
2012 · Naoe Goto, Hisashi Tsurumi, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 31
A prospective study of P‐IMVP‐16/CBDCA: a novel salvage chemotherapy for patients with aggressive non‐Hodgkin's lymphoma who had previously received CHOP therapy as first‐line chemotherapy
2002 · Michio Sawada, Hisashi Tsurumi, et al. · European Journal Of Haematology · 30
Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens
2011 · Naoe Goto, Hisashi Tsurumi, et al. · European Journal Of Haematology · 29
Phase II study of the tetrahydropyranyl adriamycin–cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma
2011 · Senji Kasahara, Takeshi Hara, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 28
Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anaemia by bone marrow stem cell expression of the tumour necrosis factor receptor
2002 · Senji Kasahara, Takeshi Hara, et al. · British Journal of Haematology · 23
Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma
2009 · Takeshi Hara, Hisashi Tsurumi, et al. · Journal of Cancer Research and Clinical Oncology · 22
Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B‐cell lymphoma treated with the R‐ CHOP regimen
2013 · Nobuhiko Nakamura, Naoe Goto, et al. · European Journal Of Haematology · 19
CHOP or THP‐COP regimens in the treatment of newly diagnosed peripheral T‐cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin
2015 · Yuhei Shibata, Takeshi Hara, et al. · Hematological Oncology · 16
Serum soluble Fas level determines clinical outcome of patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP
2009 · Takeshi Hara, Hisashi Tsurumi, et al. · Journal of Cancer Research and Clinical Oncology · 16
Prognostic impact of the controlling nutritional status score in patients with peripheral T-cell lymphoma
2021 · Nobuhiko Nakamura, Nobuhiro Kanemura, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 15
Immunosuppressive therapy for myelodysplastic syndrome: efficacy of methylprednisolone pulse therapy with or without cyclosporin A
2003 · Toshiki Yamada, Hisashi Tsurumi, et al. · Journal of Cancer Research and Clinical Oncology · 15
Polaprezinc for prevention of oral mucositis in patients receiving chemotherapy followed by hematopoietic stem cell transplantation: A multi‐institutional randomized controlled trial
2020 · Junichi Kitagawa, Ryo Kobayashi, et al. · International Journal of Cancer · 14
PDF
Therapeutic strategy of untreated de novo acute myeloid leukemia in the elderly: the efficacy of continuous drip infusion with low dose cytarabine and etoposide
2007 · Hisashi Tsurumi, Nobuhiro Kanemura, et al. · Journal of Cancer Research and Clinical Oncology · 13
Follicular variant of peripheral T‐cell lymphoma mimicking follicular lymphoma: A case report with a review of the Literature
2011 · Naoe Goto, Hisashi Tsurumi, et al. · Pathology International · 12
A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemother
2016 · Takuro Matsumoto, Takeshi Hara, et al. · Hematological Oncology · 8
Continuous drip infusion of low dose cytarabine and etoposide with granulocyte colony‐stimulating factor for elderly patients with acute myeloid leukaemia ineligible for intensive chemotherapy
2007 · Nobuhiro Kanemura, Hisashi Tsurumi, et al. · Hematological Oncology · 8
PDF
Works count: 60
Citation count: 790
H-index: 16
I10-index: 23
Year
Topic
Type